In Vitro and in Vivo Antifungal Activities of 6-[(N-4-bromophenyl)amino]-7-chloro-5,8-quinolinediones

  • 발행 : 1997.12.01

초록

Antifungal activities of 6-[(N-4-bromophenyl)amino]-7-chloro-5,8-quinolinedione (RCK7) were tested. The MIC values of RCK7 were determined for antifungal suceptibility, in vitro against Aspergillus niger, Cryptococcus neoformans and Trichophyton mentagrophyte by standard agar streak method. In vitro, RCK7 showed more potent antifungal activity than fluconazole and ketoconazole. Also, RCK7 was tested for in vivo antifungal activity in the treatment of systemic infection with Candida albicans in normal mice. The therapeutic potential of RCK7 had been assessed by evaluating their survival rate against systemic infections compared with that of ketoconazole. $ED_{50}$ of intraperitoneally administered RCK7 ws $2.05{\pm}0.30mg/kg$ but that of ketoconazole was $8.00{\pm}0.73 mg/kg$, respectively. When RCK7 was administered intravenously at the $ED_{50}$(2.05 mg/kg). the colony counts of Candida albicans in the liver after 7 days and 14 days were reduced as likely as ketoconazole at the $ED_{50}(8.00 mg/kg)$, and the better survival rates than ketoconazole's were achieved after 14 days. The results suggest that RCK7 may be a potent antifungal agent.

키워드

참고문헌

  1. New Approaches for Antifungal Drugs The need for antifungal drugs Clark,A.C.;Fernandes,P.B.(eds.)
  2. Antimicrob. Agents Chemother. v.33 Fluconazole treatment of candidiasis in normal and diabetic rats Fisher,M.A.;Lee,P.G.;Tarry,W.F.
  3. Science v.264 Human mycoses: Drugs and targets for emerging pathogens Georgopapadakou;N.H.;Walsh,J.
  4. Recent advances in the Chemistry of Anti-infective Agents Atovaquone-A novel agent for the treatment of malaria, PCP and toxoplasmosis Hudson,A.T.;Bentley,P.H.(ed.);Ponsford,R.(ed.)
  5. Ger. Offen., DE 4,208,874 Fungicides based on amino-substituted quinoline-quinones Jeschke,P.;Linder,W.;Mueller,N.;Dehne,H.W.
  6. Antibiotics in Laboratory Medicine(3rd ed.) Antifugal drug Mcginnis,M.R.;Rindali,M.G.;Lorian,V.(eds.)
  7. Yakhak Hoeji v.40 The evaluation of in vivo antifungal activities of 6-[(N-4-fluorophenyl)amino]-7-chloro-5,8-quinolinediones Park,Y.M.;Kim,H.J.;Kim,D.H.;Lee,I.K.;Ryu,C.K.
  8. Arch. Biochem. Biophys. v.191 The site of inhibition of mitochondrial electron transfer by coenzyme Q analogs Robert,H.;Choo,W.M.;Smith,S.C.;Marzuki,S.;Linnane,A.W.;Porter,T.H.;Folkers,K.
  9. Yakhak Hoeji v.39 The evaluation of in vivo antifungal activities and toxicities of 6-[(N-4-chlorophenyl)amino]-7-chloro-5,8-quinolinediones Ryu,C.K.;Kim,D.H.;Yun,Y.P.;Heo,M.Y.;Lee,B.M.;Jang,S.J.;Kim,H.J.;Park,Y.M.
  10. Arch. Pharm. Res. v.17 The antifungal susceptibility test of 5,8-quinolinediones against Candida species Ryu,C.K.;Kim,D.H.
  11. Arch. Pharm. Res. v.17 The synthesis of 6-(N-arylamino)-7-chloro-5,8-quinolinedoine derivatives for evaluation of antifungal activities Ryu,C.K.;Kim,H.J.
  12. Science v.266 The emerging fungal threat Sternberg,S.
  13. Antimicrob. Agents Chemother. v.38 Saperconazole therapy of murine disseminated candidiasis: Efficacy and interaction with amphotericine B Sugar,A.M.;Salibian,M.;Goldani,L.Z.
  14. Antimicrob. Agents Chemother. v.35 Fluconazole in the treatment of candidiasis in immunocompromised children Viscoli,C.;Terragna,A.